A securities class action lawsuit has been filed against Boston Scientific Corporation for allegedly making false and misleading statements about its U.S. Electrophysiology segment while concealing that its growth rate was unsustainable. Investors who purchased BSX stock between July 23, 2025 and February 3, 2026 may be eligible for compensation. The lead plaintiff deadline is May 4, 2026.
Boston Scientific Corp. (BSX)
Common Stock · Currency in USD · XNYS
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Company Info
SIC3841
Composite FIGIBBG000C0LW92
CIK0000885725
IPOMay 18, 1992
Sectorsurgical & medical instruments & apparatus
Highlights
Market Cap$93.36B
EPS$2.04
P/E Ratio30.91
Revenue$20.25B
Gross Profit$14.17B
Net Income$3.02B
Employees59,000
WSO1,486,175,167
Phone508-683-4000
Related Tickers
ALGN
Align Technology Inc
$170.66 0.00%
MMSI
Merit Medical Systems Inc
$67.70 0.00%
HOLX
Hologic Inc
$75.65 0.00%
ECL
Ecolab, Inc.
$264.28 0.00%
DVA
DaVita Inc.
$146.40 0.00%
AMN
AMN Healthcare Services
$18.20 0.00%
MDT
Medtronic plc
$86.18 0.00%
HQY
HealthEquity, Inc
$84.67 0.00%
HCA
HCA Healthcare, Inc.
$481.27 0.00%
SYK
Stryker Corporation
$332.00 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Boston Scientific Corp., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Boston Scientific Corp. (BSX) has returned -34.37% so far this year and -27.83% over the past 12 months. Looking at the last ten years, BSX has achieved an annualized return of 12.73%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
BSX
1M-12.51%
6M-35.57%
YTD-34.37%
1Y-27.83%
5Y9.86%
10Y12.73%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Boston Scientific Corp. (BSX) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.29% | -17.50% | -17.74% | -1.41% | ||||||||
| 2025 | 13.71% | 2.35% | -3.79% | 2.46% | 2.43% | 2.76% | -2.27% | 0.72% | -7.43% | 2.83% | 0.82% | -6.18% |
| 2024 | 10.09% | 2.70% | 3.23% | 5.04% | 5.53% | 2.19% | -4.42% | 10.35% | 2.57% | 0.19% | 7.51% | -1.61% |
| 2023 | -0.49% | 0.21% | 6.99% | 4.28% | -1.38% | 5.44% | -3.48% | 4.60% | -2.69% | -2.48% | 8.97% | 3.38% |
| 2022 | 0.73% | 3.01% | 0.48% | -5.48% | -3.19% | -9.41% | 10.29% | -0.84% | -3.94% | 9.95% | 6.09% | 1.69% |
| 2021 | -1.77% | 8.23% | -1.20% | 12.92% | -2.41% | -0.14% | 6.59% | -1.35% | -4.28% | -0.83% | -12.08% | 9.74% |
| 2020 | -7.98% | -11.34% | -13.22% | 18.53% | 2.81% | -6.89% | 9.67% | 6.02% | -6.12% | -11.13% | -4.36% | 7.31% |
| 2019 | 10.10% | 5.16% | -5.19% | -4.38% | 3.50% | 11.69% | -2.19% | 0.59% | -4.26% | 1.88% | 2.85% | 4.36% |
| 2018 | 12.11% | -0.62% | 0.07% | 5.55% | 5.74% | 6.72% | 3.38% | 5.99% | 6.91% | -6.71% | 3.43% | -7.22% |
| 2017 | 10.77% | 2.29% | 0.32% | 6.11% | 2.50% | 2.29% | -4.42% | 2.80% | 5.88% | -3.66% | -6.91% | -5.42% |
| 2016 | 17.09% | 3.60% | 3.18% | 3.76% | -2.30% | -1.12% | -7.09% | -7.00% | 5.72% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Boston Scientific Corp. (BSX) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of BSX compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Boston Scientific Corp. volatility is 2.34%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 43.67B | 39.40B | 35.14B | 32.47B | 32.23B | 30.78B | 30.57B | 21.00B | 19.04B | 18.10B | 18.13B | 17.04B | 16.57B | 17.15B | 21.29B | 22.13B | 25.18B |
| Equity Attributable To Parent (USD) | 24.23B | 21.77B | 19.28B | 17.57B | 16.62B | 15.33B | 13.88B | 8.73B | 7.01B | 6.73B | 6.32B | 6.46B | 6.54B | 6.87B | 11.35B | 11.30B | 12.30B |
| Equity Attributable To Noncontrolling Interest (USD) | 239.00M | 233.00M | 248.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 24.47B | 22.00B | 19.53B | 17.57B | 16.62B | 15.33B | 13.88B | 8.73B | 7.01B | 6.73B | 6.32B | 6.46B | 6.54B | 6.87B | 11.35B | 11.30B | 12.30B |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | 2.56B | 2.38B | 3.73B | 3.54B | 4.01B | 4.31B | 3.93B | 2.77B | - |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | 3.82B | 5.40B | 5.65B | 4.20B | 4.20B | 4.20B | 4.20B | 5.45B | - |
| Noncurrent Liabilities (USD) | 13.76B | 10.99B | 10.67B | 11.09B | 11.33B | 11.77B | 11.82B | 7.01B | 6.38B | 7.78B | 9.38B | 7.74B | 8.21B | 8.51B | 8.13B | 8.22B | 9.85B |
| Other Current Liabilities (USD) | 2.87B | 4.15B | 2.94B | 2.11B | 2.63B | 2.49B | 3.62B | 4.28B | 4.53B | 2.57B | 1.72B | 2.07B | 1.09B | 1.09B | 1.14B | 1.99B | 2.81B |
| Wages (USD) | 1.43B | 1.29B | 1.05B | 830.00M | 848.00M | 681.00M | 708.00M | 630.00M | 591.00M | 572.00M | 504.00M | 512.00M | 488.00M | 452.00M | 466.00M | 436.00M | - |
| Accounts Payable (USD) | 1.14B | 960.00M | 942.00M | 862.00M | 794.00M | 513.00M | 542.00M | 349.00M | 530.00M | 447.00M | 209.00M | 262.00M | 246.00M | 232.00M | 203.00M | 184.00M | 212.00M |
| Current Liabilities (USD) | 5.44B | 6.40B | 4.93B | 3.80B | 4.27B | 3.68B | 4.87B | 5.26B | 5.65B | 3.59B | 2.43B | 2.85B | 1.82B | 1.77B | 1.81B | 2.61B | 3.02B |
| Liabilities (USD) | 19.20B | 17.39B | 15.61B | 14.90B | 15.61B | 15.45B | 16.69B | 12.27B | 12.03B | 11.36B | 11.81B | 10.59B | 10.03B | 10.28B | 9.94B | 10.83B | 12.88B |
| Other Non-current Assets (USD) | 23.82B | 22.50B | 19.76B | 18.36B | 17.54B | 16.08B | 15.90B | 8.84B | 7.69B | 7.34B | 6.98B | 6.32B | 6.06B | 6.28B | 10.04B | 10.47B | 12.66B |
| Intangible Assets (USD) | 7.02B | 6.68B | 6.00B | 5.90B | 6.12B | 5.92B | 7.89B | 6.37B | 5.84B | 5.88B | 6.19B | 5.61B | 5.95B | 6.29B | 6.47B | 6.34B | 6.73B |
| Fixed Assets (USD) | 4.04B | 3.29B | 2.86B | 2.45B | 2.25B | 2.08B | 2.08B | 1.78B | 1.70B | 1.63B | 1.49B | 1.51B | 1.55B | 1.56B | 1.67B | 1.70B | 1.73B |
| Noncurrent Assets (USD) | 34.88B | 32.48B | 28.62B | 26.71B | 25.91B | 24.08B | 25.87B | 17.00B | 15.22B | 14.86B | 14.66B | 13.44B | 13.56B | 14.13B | 18.19B | 18.51B | 21.12B |
| Other Current Assets (USD) | 5.85B | 4.11B | 4.03B | 3.89B | 4.71B | 5.34B | 3.12B | 2.84B | 2.74B | 2.28B | 2.46B | 2.66B | 2.11B | 2.14B | 2.17B | 2.72B | 3.14B |
| Inventory (USD) | 2.94B | 2.81B | 2.48B | 1.87B | 1.61B | 1.35B | 1.58B | 1.17B | 1.08B | 955.00M | 1.02B | 946.00M | 897.00M | 884.00M | 931.00M | 894.00M | 920.00M |
| Current Assets (USD) | 8.79B | 6.92B | 6.51B | 5.76B | 6.32B | 6.69B | 4.70B | 4.00B | 3.82B | 3.24B | 3.47B | 3.61B | 3.01B | 3.02B | 3.11B | 3.62B | 4.06B |
| Assets (USD) | 43.67B | 39.40B | 35.14B | 32.47B | 32.23B | 30.78B | 30.57B | 21.00B | 19.04B | 18.10B | 18.13B | 17.04B | 16.57B | 17.15B | 21.29B | 22.13B | 25.18B |
News and Insights
A class action lawsuit has been filed against Boston Scientific Corporation alleging that the company made materially false and misleading statements regarding its U.S. electrophysiology segment's growth projections and sustainability. The complaint claims management failed to disclose material adverse trends in procedure volumes, competitive pressures, and regulatory headwinds. Investors who purchased BSX securities between July 23, 2025 and February 3, 2026 may be eligible to join the case.
A securities class action lawsuit has been filed against Boston Scientific Corporation (BSX) alleging that defendants made false and misleading statements about the company's U.S. Electrophysiology segment while concealing that its growth rate was unsustainable. The lawsuit claims management was aware of an earlier-than-anticipated tipping point, leading to a net income miss and underwhelming guidance that surprised investors. The lead plaintiff deadline is May 4, 2026.
Stock Market Today, March 30: Boston Scientific Falls After Delivering Underwhelming Trial Resultsnegative
Boston Scientific shares fell 9.02% on March 30, 2026, after the company announced results from its CHAMPION-AF clinical trial for the Watchman FLX heart implant. While the trial met all safety and efficacy endpoints, analysts considered the results underwhelming and expressed concerns that growth may not accelerate as expected. Despite the decline, analysts maintained outperform ratings, noting the stock is reasonably valued at 18x forward earnings.
Boston Scientific shares fell 9.02% to a 52-week low despite positive clinical trial results. The WATCHMAN FLX device demonstrated superior bleeding protection compared to blood thinners with comparable efficacy, while the EKOS system showed significant benefits for pulmonary embolism treatment. Despite analyst Buy ratings and a $103.45 average price target, the stock faced selling pressure following the announcements.
U.S. equity markets rebounded from seven-month lows on Monday as President Trump disclosed negotiations with Iran and Fed Chair Powell downplayed imminent rate hikes, calling tariffs a 'one-time price bump.' Treasury yields fell significantly, boosting financial, materials, and real estate sectors. Major indices gained broadly, with the S&P 500 up 0.7%, Dow up 1.1%, and Nasdaq 100 up 0.5%.
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investorsnegative
The Portnoy Law Firm has initiated a class action lawsuit on behalf of Boston Scientific investors who purchased securities between July 3, 2025 and February 3, 2026. The lawsuit alleges the company misled investors about its growth prospects and failed to disclose competitive pressures in the electrophysiology market. Boston Scientific's stock fell 17% on February 4, 2026, after reporting GAAP net income of $0.45 per share, missing its guidance range of $0.48-$0.52 per share.
Rosen Law Firm is urging Boston Scientific Corporation (BSX) investors who purchased stock between July 23, 2025 and February 3, 2026 to join a securities class action lawsuit. The lawsuit alleges that Boston Scientific made false and misleading statements about its U.S. Electrophysiology segment's sustainability, concealing that growth was unsustainable and approaching an earlier decline than anticipated. The lead plaintiff deadline is May 4, 2026.
Boston Scientific Corporation faces a class action securities fraud lawsuit alleging the company materially overstated electrophysiology (EP) market growth projections and competitive positioning of its FARAPULSE platform between July 2025 and February 2026. The stock declined 17.6% ($16.12 per share) after the company disclosed slower-than-expected U.S. EP market growth and increased competitive pressures on February 4, 2026. Investors claim management repeatedly elevated guidance while aware of unsustainable growth rates and material headwinds in the EP segment.
A securities class action lawsuit has been filed against Boston Scientific Corporation (BSX) alleging that defendants made false and misleading statements about the U.S. Electrophysiology segment's sustainability while concealing material adverse facts. The lawsuit claims management was aware of unsustainable growth rates and an earlier tipping point than anticipated, leading to a net income miss and underwhelming guidance. Investors who purchased BSX stock between July 23, 2025 and February 3, 2026 may be entitled to compensation. The lead plaintiff deadline is May 4, 2026.